维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

17篇 您的检索式：作者名="Britten CM"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-γ ELISPOT assays显示文摘	Britten CM Meyer RG Kreer T	2002	J Immunol Methods2002，259，12：	1
	2	Improving the efficacy of cancer immunotherapy显示文摘	Copier J Dalgleish AG Britten CM	2009	Eur J Cancer2009，45，8：	1
	3	Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation 显示文摘	Meyer RG Britten CM Wehler D	2007	Blood2007，109，1：	1
	4	' MIATA' - minimal infor- mation about T cell assays 显示文摘	Janetzki S Britten CM Kalos M	2009	Immunity2009，31，：	1
	5	The CIMT -monito- ring panel : a two - step approach to harmonize the enumeration of an- tigen - specific CD8 + T lymphocytes by structural and functional as- says 显示文摘	Britten CM Gouttefangeas C Welters MJ	2008	Cancer Irrmmnol Immunother2008，57，：	1
	6	Harmonization gnide- tines for HLApeptide muhimer assays derived from results of a largescale international proficiency panel of the Cancer Vaccine Consorti- um显示文摘	Britten CM Janetzki S Ben -Porat L	2009	Cancer lmmunol Immunother2009，58，：	1
	7	Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation显示文摘	Meyer RG Britten CM Wehler D	2007	Blood2007，109，：	1
	8	A phase Ⅰ vaccination study with tyrosinase in patients with stage Ⅱ melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)显示文摘	Britten CM Siepmann U	2005	Cancer Immunol Immunother2005，54，5：	1
	9	The use of HLA-A* 0201-transfected K562 as standard antigen-presenting cells for CD8+T lymphocytes in IFN-γ ELISPOT assays显示文摘	Britten CM Meyer RG Kreer T	2002	J Immunol Methods2002，259，12：	1
	10	Toward the harmonization of immune monitoring in clinical trials:Quo vadis显示文摘	Britten CM Janetzki S van der Burg SH		0，，03：	1
	11	The CIMT-Monitoring panel:A two-step approach to harmonize the enumeration of antigen-specific CD8 + T lymphocytes by structural and functional assays显示文摘	Britten CM Gouttefangeas C Schoenmaekers-Welters MJP		0，，03：	1
	12	Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the cancer vaccine Consortium (CVC)显示文摘	Britten CM Janetzki S Ben-Porat L		0，，10：	1
	13	'MIATA'-minimal information about T cell assays显示文摘	Janetzki S Britten CM Kalos M		0，，04：	1
	14	Minimal information about T cell assays:The process of reaching the community of T cell immunologists in cancer and beyond显示文摘	Britten CM Janetzki S van der Burg SH		0，，01：	1
	15	T cell assays and MIATA:The essential minimum for maximum impact显示文摘	Britten CM Janetzki S Butterfield LH		0，，01：	1
	16	hnproving the efficacy of cancer immunotherapy 显示文摘	Copier J Dalgleish AG Britten CM Finke LH Gaudernack G Gnjatic S	2009	Eur J Cancer2009，45，8：	1
	17	Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation显示文摘	Meyer RG Britten CM Wehler D	2007	Blood2007，109，1：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费